Vaccine

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

FDA feedback following the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza…

4 months ago

IMUNON Reports 2023 Financial Results and Provides Business Update

Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:…

4 months ago

Blackstone Life Sciences Announces Collaboration to Support Moderna’s Influenza Program

Blackstone Life Sciences to invest up to $750 million to support innovative mRNA technologyNEW YORK--(BUSINESS WIRE)--Blackstone (NYSE:BX) announced today a…

4 months ago

Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpointsExpects two more Phase 3…

4 months ago

Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company…

4 months ago

Dyadic to Attend Industry Events in April

JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology…

4 months ago

Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222Next-generation mRNA vaccine design offers the potential of…

4 months ago

Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models…

4 months ago

Defence’s Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine

Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

4 months ago

Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines

HAMILTON, BERMUDA, March 25, 2024 (GLOBE NEWSWIRE) -- Univercells to test proprietary mRNA vaccine delivered with Altamira’s SemaPhore™ nanoparticlesTargeting safer…

4 months ago